Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ho-Young Yhim, Chonbuk National University Hospital
ClinicalTrials.gov Identifier:
NCT01266668
First received: December 21, 2010
Last updated: November 28, 2011
Last verified: November 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2011
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
No publications provided by Chonbuk National University Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):